Načítá se...
Treatment of hepatitis C with an interferon-based lead-in phase: A perspective from mathematical modeling
BACKGROUND: The standard of care for hepatitis C virus (HCV) genotype 1 is a protease inhibitor (telaprevir or boceprevir) combined with pegylated interferon and ribavirin (P/R). A lead-in phase of P/R therapy before addition of the protease inhibitor has been used, with the aim of improving respons...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4101064/ https://ncbi.nlm.nih.gov/pubmed/24434478 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3851/IMP2725 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|